[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anemia-in-end-stage-renal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anemia-in-end-stage-renal-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100585530","phase-1-roxadustats-effect-on-heart-nutrition-and-inflammation-in-hemodialysis-patients-100585530",false,"NCT06903559","Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients","Effect of Roxadustat on Cardiovascular System and Malnutrition-Inflammation-Atherosclerosis (MIA) Syndrome in Hemodialysis Patients: A Randomized Controlled Study","ROXA-HD-MIA","Inclusion Criteria:\n\n* Age of patient is more than 18.\n* Patients who are willing to sign informed consent.\n* Patients with ESKD on chronic hemodialysis for more than 3 months.\n\nExclusion Criteria:\n\n* Current pregnancy or lactation.\n* Patients with pre-existing malignancy.\n* Patients with psychosis or on hypnotics.\n* Refuse to participate in the study.\n* Known history of hematological disorders or other known causes for anemia other than CKD or dialysis.\n* Patients with severe cardiovascular disease","ALL","18 Years",{"count":20,"type":21},46,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Patients with kidney failure who require hemodialysis often suffer from anemia (low red blood cell count), heart and blood vessel problems, and a condition involving poor nutrition, inflammation, and hardening of the arteries (called MIA syndrome). Standard treatments for anemia often involve injections and iron supplements. This study aims to see if a newer oral medication, Roxadustat, works better than these standard treatments not only for anemia but also for improving cardiovascular health and the MIA syndrome.\n\nParticipants in the study will be randomly assigned (like by chance) to one of two groups. One group will receive Roxadustat, while the other group will continue with their conventional anemia treatment. Researchers will compare the effects on heart function, markers of nutrition and inflammation, and anemia levels in both groups over a 6-month period.",[28,29,30,31],"Kidney Failure, Chronic","Malnutrition-Inflammation Syndrome","Anemia in End Stage Renal Disease","Cardiovascular Diseases (CVD)",[33,34,35,36,37],"Roxadustat","Hemodialysis","Renal Anemia","Cardiovascular Diseases","Malnutrition-Inflammation-Atherosclerosis Syndrome","RECRUITING","2025-05-08",{"date":41,"type":42},"2025-05-13","ACTUAL",{"date":44,"type":42},"2025-04-15",{"date":46,"type":21},"2025-11-01",{"name":48,"class":49},"Mansoura University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":75,"locationsCount":50},"100586636","phase-1-roxadustat-for-bone-and-neuropsychiatric-aspects-in-hemodialysis-patients-100586636","NCT06917950","Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients","Effect of Roxadustat on Bone and Neuropsychiatric Aspects in End Stage Kidney Disease Patients on Hemodialysis","ROXA-BN-HD","Inclusion Criteria:\n\n* The age of the patient is more than 18.\n* Patients who are willing to sign informed consent.\n* Patients with ESKD on chronic hemodialysis for more than 3 months.\n\nExclusion Criteria:\n\n* Current pregnancy or lactation.\n* Patients with pre-existing malignancy.\n* patients with psychosis.\n* Known history of hematological disorders or other causes of anemia other than CKD.\n* Taking medications that may significantly affect or interact with bone metabolism such as osteo-anabolics or bone resorptives during the last 6 months.",{"count":20,"type":21},[24,25],"People with severe kidney failure who need regular hemodialysis treatment often experience several health problems. These include anemia (low red blood cell count), issues with their bone health (sometimes called mineral and bone disease), and mental health challenges like depression and anxiety. They may also have problems with their nerves and muscles.\n\nRoxadustat is a newer medicine, taken as a pill, used to treat anemia caused by kidney disease. It works differently than the standard injectable medications often used.\n\nThis study aims to investigate if Roxadustat has effects beyond treating anemia in hemodialysis patients. Specifically, researchers want to see if taking Roxadustat affects patients' bone health (measured by bone density scans and blood tests) and their psychological well-being (looking at symptoms of depression and anxiety using questionnaires). The study will also use ultrasound to look at potential changes in nerves and muscles.\n\nThe study will enroll 46 patients on hemodialysis. Patients will be randomly assigned (like flipping a coin) into two groups. One group (23 patients) will receive Roxadustat three times a week, while the other group (23 patients) will continue receiving their usual conventional treatment for anemia.\n\nAll patients will be followed for 6 months. During this time, they will have regular blood tests, bone density scans (using a technique called QCT), nerve and muscle ultrasound examinations, and will complete questionnaires about their mood.\n\nResearchers will compare the results between the two groups to understand the effects of Roxadustat on bone, mood, anxiety, and neuromuscular aspects in patients undergoing hemodialysis",[63,30,64],"Kidney Failure,Chronic","Depression Anxiety Disorder",[33,34,35,66,67,68,69],"Bone Mineral Density (BMD)","Quantitative Computed Tomography (QCT)","Neuropsychiatric","Musculoskeletal Ultrasound (MSK-US)","2025-05-07",{"date":72,"type":42},"2025-05-11",{"date":44,"type":42},{"date":46,"type":21},{"name":48,"class":49},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":50},"100585781","comparing-reticulocyte-hemoglobin-and-transferrin-saturation-to-guide-iron-treatment-in-people-on-dialysis-100585781","NCT06906835","Comparing Reticulocyte Hemoglobin and Transferrin Saturation to Guide Iron Treatment in People on Dialysis","Efficacy of Reticulocyte Hemoglobin Equivalent-guided Versus Transferrin Saturation-guided Iron Supplement Protocol in Hemodialysis Patients: A Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult (age 18-80 years)\n* ESKD on chronic hemodialysis ≥ 6 months\n* EPO therapy ≥ 6 months\n* Hb \\\u003C 13.0 g\u002FdL in male, \\\u003C 12.0 g\u002FdL in female\n\nExclusion Criteria:\n\n* Serum ferritin \\> 800 ng\u002FmL or TSAT \\> 40%\n* Active infection or malignancy\n* Hematologic disease including thalassemia major, hemolysis, myelofibrosis or myelodysplastic disease\n* History of marrow suppressive or immunosuppressive medications in past 6 months\n* History of active heart failure and recent myocardial infarction \u002Fstroke in past 6 months\n* History of GI or external bleeding or receiving blood transfusion in past 6 months","80 Years",{"count":85,"type":21},160,[87],"NA","The goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (ESKD) on hemodialysis who have anemia.\n\nThe main questions it aims to answer are:\n\nCan using reticulocyte hemoglobin equivalent (RET-He) to guide intravenous (IV) iron treatment be as effective as using transferrin saturation (TSAT)?\n\nDoes the method used to guide iron treatment affect outcomes such as death, heart problems, hospitalizations, infections, or the need for blood transfusions?\n\nResearchers will compare RET-He-guided iron treatment with TSAT-guided iron treatment to see if RET-He works just as well and has similar or better outcomes.\n\nParticipants will:\n\nReceive IV iron based on either RET-He or TSAT levels\n\nHave blood tests done at the start, 3 months, and 6 months\n\nHave their doses of iron and erythropoietin (a medication to treat anemia) adjusted based on the assigned protocol\n\nBe monitored for clinical outcomes such as hospitalization, heart events, and infections",[34,30],[91,92,93,30,34],"Reticulocyte hemoglobin equivalent","Transferrin Saturation","Intravenous Iron Supplementation","2025-04-01",{"date":96,"type":42},"2025-04-04",{"date":98,"type":42},"2025-01-31",{"date":100,"type":21},"2025-09-30",{"name":102,"class":49},"King Chulalongkorn Memorial Hospital"]